VANCOUVER, British Columbia, Feb. 8, 2005 (PRIMEZONE) -- Professor Jean-Charles Quirion (a member of ProtoKinetix' Scientific Advisory Board) reports today that The National Institute Of Chemistry (ICSN) has found no cytotoxicity on the very sensitive vero cells. As previously announced, the first in vitro assays performed on KB cells showed that synthetic AFGPs were totally lacking cytotoxicity even in high doses. This additional clinical confirmation of the safety of these molecules permits ProtoKinetix to immediately introduce AFGP into the various application areas of cell stabilization.
One of the major concerns of any pharmaceutical entity, prior to the use of a new technology or molecule, is the risk/reward ratio covering benefits, as opposed to any toxic effects that may occur. By confirming the complete absence of any level of observed toxicity, PKTX intends to aggressively introduce this family of unique AFGP molecules to the pharmaceutical, haematology and cosmetic industries.
About ProtoKinetix:
ProtoKinetix Inc. (OTCBB:PKTX) is a scientific development company whose mission is the advancement of human health care. The Company's first entry into the commercial marketplace will be the launch of the first synthetically replicated antifreeze glycoprotein (AFGP). PKTX has developed a unique business model that brings together a vast pool of world recognized intellectual talent in a networked environment. This integrated scientific approach combines the disciplines of physics, chemistry and molecular biology in order to fast-track product development.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.
On behalf of the Board of Directors,
Dr. John Todd, President